A Proof-of-concept Study to Assess the Effect of MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants.

Trial Profile

A Proof-of-concept Study to Assess the Effect of MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2016

At a glance

  • Drugs MMV 390048 (Primary)
  • Indications Falciparum malaria
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 19 May 2016 Status changed from recruiting to completed.
    • 17 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 05 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top